Osimertinib Tablets
Form: Oral Tablets
Strength: 40 mg, 80 mg
Reference Brands: Tagrisso® (US & EU)
Category: Oncology Cancer Care
Osimertinib Tablets are a third-generation tyrosine kinase inhibitor (TKI) used in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), including T790M resistance mutations. Marketed under the brand name Tagrisso®, Osimertinib selectively targets and inhibits EGFR mutations, providing a more precise treatment for metastatic NSCLC. Available in 40 mg and 80 mg tablet strengths, Osimertinib offers significant benefits in advanced lung cancer care. Manufactured under GMP-compliant conditions, it is an effective and reliable solution for US and EU pharmaceutical distributors looking to provide cutting-edge oncology treatments in precision medicine.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details Get Enquiry
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details Get Enquiry
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details Get Enquiry
Ifosfamide
Strength: 1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details Get Enquiry